Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
CC transcript
Acq. announced
CASTLE BIOSCIENCES INC (CSTL) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/02/2023 8-K Quarterly results
06/01/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
02/28/2023 8-K Investor presentation, Quarterly results
Docs: "Castle Biosciences Reports Fourth Quarter and Full-Year 2022 Results Full-year 2022 revenue was up 46% over 2021 to $137 million, meeting top end of guided range Delivered 44,419 total test reports in 2022, an increase of 58% compared to 2021",
"137.0 2017 2018 2019 2020 2021 2022 10,614 13,445 17,055 18,185 28,145 44,419 2017 2018 2019 2020 2021 2022"
01/20/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/09/2023 8-K Quarterly results
12/28/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/15/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/02/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
06/08/2022 8-K Quarterly results
06/03/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
05/02/2022 8-K Quarterly results
04/07/2022 8-K Entry into a Material Definitive Agreement  Interactive Data
04/04/2022 8-K Acquisition/merger/asset purchase announced
Docs: "Agreement and Plan of Merger, by and among the Company, AltheaDx, Inc., Acorn Merger Sub, Inc. and Fortis Advisors LLC"
03/17/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "FOURTH AMENDMENT TO STANDARD OFFICE LEASE"
02/28/2022 8-K Investor presentation, Quarterly results
Docs: "Castle Biosciences Reports Fourth Quarter and Full-Year 2021 Results Full-year 2021 revenue was up 50% over 2020 to $94.1 million, beating expectations Growth of 55% year over year in total GEP testing volume",
"F O R W A R D"
01/14/2022 8-K/A Financial Statements and Exhibits  Interactive Data
Docs: "Consent of Independent Auditors",
"Consolidated Financial Statements for the Nine Months Ended",
"CASTLE BIOSCIENCES, INC. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION"
01/10/2022 8-K Investor presentation
Docs: "Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2021 Results 2021 Estimated revenue is expected to meet or exceed top end of guided range of $89-93 million",
"F O R W A R D"
01/05/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "EMPLOYMENT SEPARATION AGREEMENT",
"MASTER SERVICES AGREEMENT"
12/06/2021 8-K Quarterly results
12/03/2021 8-K Quarterly results
11/08/2021 8-K Investor presentation, Quarterly results
Docs: "Castle Biosciences Announces Third Quarter 2021 Results Q3 2021 revenue grew by 54% over the prior year quarter to $23.5 million Q3 2021 total dermatology test report volume of 7,352",
"2 0 2 1 A"
10/19/2021 8-K Acquisition/merger/asset purchase announced
Docs: "Castle Biosciences to Acquire Cernostics Fuels mid- and long-term growth with TissueCypher® platform enabling GI franchise Acquisition will expand Castle’s estimated U.S. TAM by approximately $1 billion",
"2 0 2 1 C"
09/09/2021 8-K Investor presentation
Docs: "2 0 2 1 H"
08/09/2021 8-K Investor presentation, Quarterly results
Docs: "Castle Biosciences Announces Second Quarter 2021 Results Q2 2021 revenues of $22.8 million, compared to $12.7 million in Q2 2020 Q2 2021 total dermatology test report volume of 6,539",
"F O R W A R D"
07/16/2021 8-K Quarterly results
06/14/2021 8-K Quarterly results
05/10/2021 8-K Quarterly results
04/09/2021 8-K Quarterly results
03/08/2021 8-K Quarterly results
01/13/2021 8-K Quarterly results
12/22/2020 8-K Termination of a Material Definitive Agreement  Interactive Data
12/16/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, by and among Castle Biosciences, Inc., SVB Leerink LLC and Robert W. Baird & Co. Incorporated, as representatives of the several underwriters named therein",
"Opinion of Cooley LLP",
"FRIENDSWOOD, Texas – Dec. 14, 2020",
"FRIENDSWOOD, Texas – Dec. 15, 2020"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy